BioAtla Announces Share Consolidation
BioAtla, Inc., a clinical-stage biotechnology company, announced a 50-for-1 share consolidation effective April 6, 2026, aimed at increasing its stock price to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The consolidation aligns with an approved merger where every fifty shares will convert into one share of common stock. Bi…